🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Mankind Pharma Limited MANKIND NIFTY_MIDNSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.mankindpharma.com
Company Profile ↓
₹2,562.00
+0.75% 1Y
Mkt Cap₹1.06 L Cr
P/E55.36
P/B6.35
Div. Yield0.08%
52W High₹2,695.44
52W Low₹1,927.40
Book Value₹394.85
EPS (TTM)₹46.28

Company Overview

Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory diseases, etc. It also provides consumer healthcare products, such as condoms, pregnancy detection kits, oral contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. In addition, the company engages in the trading and exporting of pharmaceutical and health care products; manufacture of packing materials, ayurvedic products, and consumer goods; real estate, leasing, and hospitality businesses; trading of agricultural products; and provision of IT services. It offers its products under the Manforce, Moxi Kind-Cv, AmLokind-At, Unwanted-Kit, Prega News, Dydroboon, Gudcef, Candi Force, Glimestar-M, Telmikind-Am, Nurokind-Gold, Telmikind-H, Nurokind-Lc, Telmikind, Vomikind, Cefakind, Nurokind Plus-Rf, Gudcef-Cv, Monticope, and Asthakind-Dx brand names. Mankind Pharma Limited was incorporated in 1991 and is based in New Delhi, India.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 14.3% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 17.7% CAGR over the past five years.

Healthy Margins

Operating margin of 19.9% supports profitability.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.39.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹14,277.64 Cr (+17.0% YoY); net profit ₹1,912.93 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +17.0%, earnings -3.9%.
  • 5-Year Trend Long-term compounding — revenue CAGR 17.7%, profit CAGR 14.3%.

Growth & Price Performance

Compounded Sales Growth

5 Years:17.73%
1 Year:16.96%

Compounded Profit Growth

5 Years:14.28%
1 Year:-3.92%

Stock Price Performance

1 Year:+0.75%
6 Months:+16.41%
3 Months:+21.74%
1 Month:+8.73%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 83% of range
₹1,927.40 ₹2,695.44
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)61.55 · Neutral
Price Performance
1M+8.73%
3M+21.74%
6M+16.41%
1Y+0.75%
Valuation vs Sector

P/E of 55.36 is above the sector median of 39.97 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 17.7% over 5 years.
  • Profit CAGR of 14.3% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading at a high P/E of 55.4.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
55.36
Industry PE
39.97
Forward P/E
35.85
PEG Ratio
-
Book Value
₹394.85
Price to Book
6.35
P/S
7.25
EV/EBITDA
29.72
Dividend Yield
0.08%

Growth (CAGR)

Revenue 5Y
17.73%
Profit 5Y
14.28%
Revenue (YoY)
16.96%
Earnings (YoY)
-3.92%

Profitability & Returns

ROCE
13.75%
ROE
11.74%
ROA
6.81%
Profit Margin
13.40%
Op Margin
19.86%
Gross Margin
70.94%
EPS (Latest Qtr)
₹13.41
EPS (TTM)
₹46.28

Balance Sheet & Liquidity

Debt/Equity
0.39
Quick Ratio
0.74
Current Ratio
1.07
Debt
₹6,311.54 Cr
Total Assets
₹28,079.53 Cr
Current Assets
₹6,954.20 Cr
Working Capital
₹446.95 Cr

Ownership

Promoter Holding
75.40%
Chg in Prom Hold
2.74%
FII / Inst Holding
20.15%
Chg in FII Hold
-0.03%

Financial Snapshot

Enterprise Value
₹1.06 L Cr
Total Revenue (TTM)
₹14,277.64 Cr
EBITDA
₹3,852.26 Cr
Free Cash Flow
₹2,384.05 Cr
Operating Cash Flow
₹3,121.29 Cr
Shares Outstanding
₹41.28 Cr
Gross Margin
70.94%
Payout Ratio
2.16%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA 2,562.00 55.36 ₹1.06 L Cr 0.08% 13.75% 11.74% 17.73% 14.28%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 2,053.00 Cr2,579.00 Cr2,708.00 Cr2,607.00 Cr2,422.00 Cr2,868.00 Cr3,061.00 Cr3,198.79 Cr3,079.37 Cr3,570.35 Cr3,697.00 Cr3,567.20 Cr3,442.93 Cr
Cost of Revenue -------931.51 Cr875.38 Cr1,053.59 Cr-977.99 Cr958.37 Cr
Gross Profit -------2,267.28 Cr2,203.99 Cr2,516.76 Cr-2,589.21 Cr2,484.56 Cr
Operating Expenses 1,636.00 Cr1,924.00 Cr2,025.00 Cr2,000.00 Cr1,836.00 Cr2,196.00 Cr2,214.00 Cr1,638.46 Cr1,751.67 Cr1,888.67 Cr2,776.00 Cr1,892.38 Cr1,777.76 Cr
Operating Income 332.00 Cr568.00 Cr587.00 Cr496.00 Cr486.00 Cr569.00 Cr747.00 Cr628.82 Cr452.32 Cr628.09 Cr699.00 Cr696.83 Cr706.80 Cr
EBITDA 417.00 Cr655.00 Cr683.00 Cr606.00 Cr586.00 Cr672.00 Cr847.00 Cr896.43 Cr936.84 Cr929.82 Cr921.00 Cr888.80 Cr1,024.00 Cr
Interest Expense 5.00 Cr6.00 Cr9.00 Cr9.00 Cr9.00 Cr11.00 Cr7.00 Cr220.93 Cr190.54 Cr170.65 Cr170.00 Cr157.20 Cr141.75 Cr
Pretax Income 377.00 Cr624.00 Cr641.00 Cr562.00 Cr572.00 Cr666.00 Cr849.00 Cr488.33 Cr515.43 Cr540.49 Cr624.00 Cr509.00 Cr659.17 Cr
Tax Provision 82.94 Cr131.04 Cr128.20 Cr101.16 Cr97.24 Cr119.88 Cr186.78 Cr110.46 Cr86.44 Cr95.87 Cr106.08 Cr95.12 Cr99.75 Cr
Net Income 294.00 Cr494.00 Cr511.00 Cr460.00 Cr477.00 Cr543.00 Cr659.00 Cr380.23 Cr420.77 Cr438.32 Cr520.00 Cr408.75 Cr554.35 Cr
Diluted EPS 7.1312.1512.5111.3311.7613.3916.319.4410.1810.6012.399.8913.41

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 3,334.00 Cr5,865.00 Cr6,214.00 Cr-8,749.43 Cr10,259.29 Cr12,207.44 Cr14,277.64 Cr
Cost of Revenue ----2,962.33 Cr3,257.31 Cr3,569.18 Cr4,149.58 Cr
Gross Profit ----5,787.11 Cr7,001.98 Cr8,638.26 Cr10,128.06 Cr
Operating Expenses 2,748.00 Cr4,427.00 Cr4,565.00 Cr-4,145.49 Cr4,762.71 Cr6,122.11 Cr7,292.99 Cr
Operating Income 547.00 Cr1,339.00 Cr1,530.00 Cr-1,641.62 Cr2,239.27 Cr2,516.15 Cr2,835.07 Cr
EBITDA 586.00 Cr1,438.00 Cr1,649.00 Cr-2,037.43 Cr2,824.01 Cr3,558.44 Cr3,852.26 Cr
Interest Expense 2.00 Cr23.00 Cr21.00 Cr-40.27 Cr27.82 Cr420.89 Cr633.40 Cr
Pretax Income 621.00 Cr1,438.00 Cr1,692.00 Cr-1,671.24 Cr2,397.94 Cr2,516.33 Cr2,332.68 Cr
Tax Provision 180.09 Cr388.26 Cr406.08 Cr-361.56 Cr457.15 Cr509.74 Cr394.58 Cr
Net Income 445.00 Cr1,056.00 Cr1,293.00 Cr-1,281.86 Cr1,912.90 Cr1,990.96 Cr1,912.93 Cr
Diluted EPS 219.3325.7231.5935.7832.0047.6849.1946.28

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 3,022.00 Cr5,065.00 Cr6,360.00 Cr-9,715.45 Cr11,963.25 Cr27,759.53 Cr28,079.53 Cr
Current Assets ----4,327.87 Cr6,568.22 Cr6,988.27 Cr6,954.20 Cr
Cash & Equivalents ----304.82 Cr382.01 Cr407.36 Cr391.69 Cr
Inventory ----1,498.46 Cr1,553.46 Cr2,093.71 Cr2,144.48 Cr
Receivables ----576.42 Cr848.28 Cr1,538.34 Cr1,729.51 Cr
Total Liabilities ----2,092.16 Cr2,387.46 Cr13,191.35 Cr11,518.48 Cr
Current Liabilities ----1,863.14 Cr2,119.73 Cr5,663.56 Cr6,507.25 Cr
Long Term Debt ----23.15 Cr24.87 Cr5,526.19 Cr2,821.23 Cr
Total Debt 0131.00 Cr241.00 Cr-170.37 Cr207.17 Cr8,511.45 Cr6,311.54 Cr
Total Equity 2,055.00 Cr3,485.00 Cr4,722.00 Cr-7,435.22 Cr9,363.09 Cr14,332.39 Cr16,300.34 Cr
Shares Outstanding ----40.06 Cr40.06 Cr41.26 Cr41.28 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -1,070.00 Cr1,137.00 Cr-1,813.30 Cr2,152.44 Cr2,413.38 Cr3,121.29 Cr
Investing Cash Flow --436.00 Cr-1,222.00 Cr--1,054.13 Cr-2,081.69 Cr-12,682.95 Cr-196.42 Cr
Financing Cash Flow --531.00 Cr-8.00 Cr--739.73 Cr5.27 Cr10,232.56 Cr-2,952.69 Cr
Capital Expenditure --217.00 Cr-311.00 Cr--832.07 Cr-389.21 Cr-530.76 Cr-737.24 Cr
Free Cash Flow -853.00 Cr826.00 Cr-981.23 Cr1,763.23 Cr1,882.62 Cr2,384.05 Cr
Net Change in Cash -103.00 Cr-92.00 Cr-19.44 Cr76.02 Cr-46.41 Cr-27.82 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % ----66.1%68.3%70.8%70.9%
Operating Margin % 16.4%22.8%24.6%-18.8%21.8%20.6%19.9%
Net Margin % 13.3%18.0%20.8%-14.7%18.6%16.3%13.4%
ROE % 21.7%30.3%27.4%-17.2%20.4%13.9%11.7%
ROCE % ----20.9%22.7%11.4%13.1%

Shareholding Pattern

Insiders
75.40%
Institutions
20.15%
Public Float
81.91%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for MANKIND

Google News hu, 25 Jun 2026

MANKIND Forecast — Price Target — Prediction for 2027 - TradingView

<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE02TkNkUjRES2NnaVdSMG4xXzBWalVnLV9VSU41M3VQdkFmQWhjcTczV3AzeGkxWWhmWk15TjloamhaTTdXVHJ6R2ZFN1ZRRDJ2UEJoMUFPVnJUdENQZDI4R2dsbVFQRTMyWkh4M0pkc2hLWDJKMG1JamN3?oc=5" target="_blank">MAN…

Google News Mon, 13 Jul 2026

Analysts Are Updating Their Mankind Pharma Limited (NSE:MANKIND) Estimates After Its Yearly Results - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7gFBVV95cUxQZjNaWTFOM2JFeGNZYTBKa1RpNm8tN3dpWUE5Rlo3V0NISVMtbFA2YnNsZS04UWw5MEo1djNoYkdUZHNXdHhrazlyXzM1OUwtSmZQbTJNWEpKWUstSGdDT2FFRE0zVV8xYldiNkl1RzNlNE4xblNPSmR3QWlCNllVTjQxb2NuVUk1Mm5FY0…

Google News ue, 14 Jul 2026

Kotak Research rejigs model portfolios; adds SBI Life, TCS, CRISIL, DCB Bank, removes Mankind, Dixon, Info... - Moneycontrol.com

<a href="https://news.google.com/rss/articles/CBMi_AFBVV95cUxPSUIzWGxKTmV2UVZROS1rQ0ZNUFE0ck5wZXJiYXg3QWpVYWRjcVlOYXBJVmZhMFhOWlM3ZlJoZklpU2Eyd1E0d2hDNHpyeWlkVDNIOVNYTzdselFwR2FTU1N1RndTTm9fV3lRV01IWnZyRnJTVmtodnpOLThoeS1PTGFXWTFia2lfRXU1VW…

Google News ue, 07 Jul 2026

Top stocks to buy today: Stock market recommendations for July 7, 2026 - check list - The Times of India

<a href="https://news.google.com/rss/articles/CBMiqwJBVV95cUxNLWtiWjVvRkVkd3pXdm9fTk5GSG5SYU1RckQwSmN5YmRXUk8wZWNyMF8zQ2xwYzhaaFo5cHpWQlJjR2xLOGw1ako4OUQ1YmVGZDR1LXducnpQbWVrZkpvSVdQSXV1MjZzVGVVbnQ4Y2p0ejh2dDV2VnBsYnU2RzVDTzlnOWRfdDlZUkkySn…

Google News ue, 07 Jul 2026

Stock Picks Today: HDFC AMC, Trent, Titan, Mankind Pharma And More On Brokerages' Radar - NDTV Profit

<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxQaU1DU1lDVm9YdVRlM2lKMTFUVHd5ZkNCZ0lvSUc3cF9NUjF3SUZ6MkZLRmxQa3hhMXJQNjEta3o2UG1kTkRoRjliQnI1ZHVLTXFXMlZrVzcya3p0TThZa2ZseEdCTGVUY0JlQXFBUTVzTFRqZ1pPbklySXRDNmY0NUxGdmdjV01SZ2VyTT…

Google News Wed, 01 Jul 2026

Mankind Pharma sets e-voting dates for 35th AGM - scanx.trade

<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxPQ2RUaFR5Q0ZCaTUyYnQwT2F0cXQxMkdJR3VLZ2t1ck9fNkRsd3dPZHBQblFyVEpDckdabV9rM1FCcG1vVDhJRVdWU1FBQ0VkNjlEUURTTHdnaGZTUjVFd2RRZkZRdDk4WWVJZWQ5bWFXLTdSNjhsVUFIUGMxOUpfMFo2SXpCdTJlemFuSS…

MANKIND — Frequently Asked Questions

What is the current share price of Mankind Pharma Limited (MANKIND)?

As of 2026-07-15 09:52 IST, Mankind Pharma Limited (MANKIND) trades at ₹2,562.00 on NSE. Its 52-week range is ₹1,927.40 to ₹2,695.44.

What is the market capitalisation of MANKIND?

Mankind Pharma Limited (MANKIND) has a market capitalisation of ₹1.06 L Cr on NSE.

What is the P/E ratio of MANKIND?

MANKIND trades at a trailing price-to-earnings (P/E) ratio of 55.36. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 6.35.

Does MANKIND pay a dividend?

Mankind Pharma Limited (MANKIND) currently offers a dividend yield of 0.08%.

What is the return on equity (ROE) of MANKIND?

MANKIND has a return on equity (ROE) of 11.74%. Its return on capital employed (ROCE) is 13.75%.

Is MANKIND a good stock to buy?

This page provides a data-driven analysis of Mankind Pharma Limited (MANKIND), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space